肿瘤细胞治疗研究
英文原题：Bone marrow mesenchymal stromal cells and multiple myeloma: Cellular interactions and therapeutic opportunities.
骨髓间充质基质细胞（BM-MSCs）是骨髓微环境的重要组成部分，支持造血细胞，并在免疫调节、组织修复和再生中发挥关键作用。
骨髓间充质基质细胞（BM-MSC）是骨髓微环境的重要组成部分，可支持造血细胞，并在免疫调节、组织修复和再生中发挥关键作用。除具备向中胚层谱系分化的能力外，BM-MSC还具有显著免疫调节作用。BM-MSC在多发性骨髓瘤（MM）病理生物学中的作用一直是研究重点，因为这些细胞可通过多种分子相互作用促进浆细胞在骨髓中的存活、增殖和滞留。对MM患者BM-MSC进行蛋白质组和基因组表征后发现，其基因表达异常、细胞因子产生失调且呈免疫抑制表型；这些改变均会促进MM细胞增殖和治疗耐药。目前正在研究多种靶向BM-MSC的MM替代疗法，包括破坏细胞间通讯、抑制可溶性生长因子，以及开发CAR-T细胞等免疫疗法。
Bone marrow mesenchymal stromal cells (BM-MSCs) are essential components of the bone marrow microenvironment that support hematopoietic cells and play key roles in immune regulation, tissue repair, and regeneration. In addition to their capacity to differentiate into mesodermal lineages, BM-MSCs exhibit significant immunomodulatory effects. The role of BM-MSCs in the pathobiology of multiple myeloma (MM) has been a focus of research, as these cells promote the survival, proliferation, and retention of plasma cells in the bone marrow through various molecular interactions. Proteomic and genomic characterisation of BM-MSCs in patients with multiple myeloma (MM) has revealed aberrant gene expression, dysregulated cytokine production, and an immunosuppressive phenotype, all of which promote MM cell proliferation and treatment resistance. Several alternative treatment approaches for MM targeting BM-MSCs, including disruption of cell-cell communication, inhibition of soluble growth factors, and the development of immunotherapies such as CAR-T cells, are under investigation.
MEMBER ACCOUNT
登录成功会直接打开下一页。
